Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 2181
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
LETTER TO THE EDITOR
Year : 2012  |  Volume : 60  |  Issue : 2  |  Page : 159

Toxic optic neuropathy


1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 Department of Ophthalmology and Visual Sciences, Khoo Teck Puat Hospital, Alexandra Health; Eye Clinic, Jurong Medical Centre, Singapore

Date of Web Publication20-Mar-2012

Correspondence Address:
Sanjay Srinivasan
Ophthalmology and Visual Sciences, Khoo Teck Puat Hospital, Alexandra Health, 90 Yishun Central, 768828
Singapore
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.94065

Rights and Permissions

How to cite this article:
Lee E, Srinivasan S. Toxic optic neuropathy. Indian J Ophthalmol 2012;60:159

How to cite this URL:
Lee E, Srinivasan S. Toxic optic neuropathy. Indian J Ophthalmol [serial online] 2012 [cited 2019 Aug 21];60:159. Available from: http://www.ijo.in/text.asp?2012/60/2/159/94065

Dear Editor,

We read with interest the article titled "Toxic optic neuropathy" (TON) [1] and would like to commend the authors for an excellent overview of TON. We would like to include the roles of sildenafil citrate and dapsone as causative factors for TON due to their increasing and/or pre-existing widespread use in India.


  Sildenafil Citrate Top


Since becoming available in 1998, sildenafil has been widely known for treatment of erectile dysfunction.

We are aware that the use of sildenafil has been growing steadily in India since its launch in 2005, its targeted market being India's top 30 cities. A press release from Pfizer India in 2006 quoted that it successfully captured 1.8% of its targeted market since its launch and estimated that it was confident of increasing its capture to 10%, 2 years from the launch date. [2] India is the second most populous country in the world with over 1.18 billion people. If Pfizer's targeted market did not restrict to India's top 30 cities only, but extended to the whole of India, targeting all males above 65 years old, a 10% capture would amount to an estimated 2 million users.

Sildenafil is believed to cause non-arteritic anterior ischemic optic neuropathy (NA-AION). Though the connection between the two does not meet World Health Organization (WHO) criteria for a cause-and-effect relationship, there have been numerous case reports of optic neuropathy from its use. The association of sildenafil and NA-AION may be secondary to the vascular effects induced by this drug. Nitric oxide induced vasodilatation may precipitate NA-AION by interfering with vascular autoregulation at the optic nerve or by inducing systemic hypotension. Alternatively, the drug may be directly toxic at the optic nerve as excessive nitric oxide has been postulated to damage retinal ganglion cell axons. [3]


  Dapsone Top


Seventy percent of the approximately quarter of a million people affected with leprosy throughout the world still resides in India. A study done by the Foundation for Medical Research (FMR) in 2007 in one rural and one urban setting in Maharashtra, India, showed a high prevalence of leprosy (PR = 6.7 and 2.6 per 10,000, as against the state average of 0.7/10,000). [4]

Dapsone is an indispensable drug used in the treatment of leprosy. It was first used singly in the 1940s and then as part of the multi-drug therapy (MDT) in 1981.

The most prominent side effect of dapsone is dose-related hemolysis which is postulated to be the pathogenesis of NA-AION, possibly due to delayed blood flow and decreased oxygenation of the optic nerve head. [5]

With the high prevalence of leprosy in India, and a consequentially high usage of dapsone, this is an important drug to consider as a cause of TON in India.

It is therefore pertinent to be aware of the increasing usage of existing drugs known to already cause TON, especially within the country or the region one is practicing in. This enables a more clinically relevant and accurate diagnosis, securing the future of sight in our patients.

 
  References Top

1.
Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol 2011;59:137-41.   Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Pfizer India [Internet]. India: Pfizer India; c2009. Press Releases: Viagra TM exceeds targets in sixty days!; [about 2 screens]. Available from: http://www.pfizerindia.com/eNewsWebsite/news1.aspx?id=4AiXNAy4t2k=. [Updated 2006 Mar 6; Cited 2011 May 1].  Back to cited text no. 2
    
3.
Lannin BK, Rod F. Optic Nerve Disorders. 2 nd ed. USA: Oxford University Press; 2007.  Back to cited text no. 3
    
4.
Shetty VP, Thakar UH, D'souza E, Ghate SD, Arora S, Doshi RP, et al. Detection of previously undetected leprosy cases in a defined rural andurban area of Maharashtra, Western India. Lepr Rev 2009;80:22-33.  Back to cited text no. 4
[PUBMED]    
5.
Chalioulias K, Mayer E, Darvay A, Antcliff R. Anterior ischemic optic neuropathy associated with dapsone. Eye (Lond) 2006;20:943-5.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Sildenafil Citrate
Dapsone
References

 Article Access Statistics
    Viewed2292    
    Printed22    
    Emailed0    
    PDF Downloaded187    
    Comments [Add]    

Recommend this journal